Formosa Pharmaceuticals, Inc. — Investor Relations & Filings
Formosa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies within the fields of ophthalmology, oncology, and anti-infectives. The company utilizes its proprietary Activus Pure Nano-technology (APNT®) platform to enhance the formulation of poorly soluble drugs, improving bioavailability and efficacy. Its lead product, APP13007, is a clobetasol propionate ophthalmic suspension developed for the treatment of post-operative inflammation and pain following ocular surgery, which has received regulatory approval in the United States. Formosa Pharmaceuticals focuses on the 505(b)(2) regulatory pathway and the development of antibody-drug conjugates (ADCs). The company actively pursues global licensing and co-development partnerships to advance its pipeline of high-value therapeutic assets.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | |
| 115年04月董事會成員及持股 | 2026-05-05 | Chinese | |
| 115年4月背書保證與資金貸與 | 2026-05-04 | Chinese | |
| 115年4月營業收入 | 2026-05-04 | Chinese | |
| 115年年報及股東會資料 — 2026_6838_20260525F13.pdf | 2026-04-27 | Chinese | |
| 115年年報及股東會資料 — 2026_6838_20260525FE2.pdf | 2026-04-24 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41265890 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41265882 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 40916642 | 115年4月背書保證與資金貸與 | 2026-05-04 | Chinese | ||
| 40916637 | 115年4月營業收入 | 2026-05-04 | Chinese | ||
| 37237117 | 115年年報及股東會資料 — 2026_6838_20260525F13.pdf | 2026-04-27 | Chinese | ||
| 36052267 | 115年年報及股東會資料 — 2026_6838_20260525FE2.pdf | 2026-04-24 | English | ||
| 36052226 | 115年年報及股東會資料 — 2026_6838_20260525FE1.pdf | 2026-04-24 | English | ||
| 36052196 | 115年年報及股東會資料 — 2026_6838_20260525F02.pdf | 2026-04-24 | Chinese | ||
| 36052153 | 115年年報及股東會資料 — 2026_6838_20260525F01.pdf | 2026-04-24 | Chinese | ||
| 34653592 | 114年第4季財務報告書 — 202504_6838_AIC.pdf | 2026-04-17 | English | ||
| 34653590 | 114年第4季財務報告書 — 202504_6838_AIA.pdf | 2026-04-17 | English | ||
| 34653589 | 114年第4季財務報告書 — 202504_6838_AI3.pdf | 2026-04-17 | Chinese | ||
| 34653587 | 114年第4季財務報告書 — 202504_6838_AI1.pdf | 2026-04-17 | Chinese | ||
| 34653586 | 114年第4季財務報告書 — 202503_6838_AIA.pdf | 2026-04-17 | Chinese | ||
| 34653584 | 114年第4季財務報告書 — 202503_6838_AI1.pdf | 2026-04-17 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Initiator Pharma A/S
Clinical-stage company developing drugs for central and per…
|
INIT | DK | Professional, scientific and te… |
|
Inmolecule Nanotech, S.A.
Develops nanoparticles from plant compounds for biomedical …
|
MLINA | ES | Professional, scientific and te… |
|
InNexus Biotechnology Inc.
Develops enhanced monoclonal antibodies and diagnostics usi…
|
IXSBF | CA | Professional, scientific and te… |
|
Inotiv, Inc.
A CRO providing nonclinical drug development services and r…
|
NOTV | US | Professional, scientific and te… |
|
INOVIQ LTD
Develops exosome and precision diagnostics for early cancer…
|
IIQ | AU | Professional, scientific and te… |
|
InSilico Medicine Cayman TopCo
Biotechnology company transforming drug discovery using pro…
|
3696 | KY | Professional, scientific and te… |
|
IntegraGen
Provides genomic services for cancer and rare diseases, tra…
|
ALINT | FR | Professional, scientific and te… |
|
Intellia Therapeutics, Inc.
A clinical-stage genome editing company developing therapeu…
|
NTLA | US | Professional, scientific and te… |
|
InterDigital, Inc.
An R&D company licensing foundational technologies for mobi…
|
IDCC | US | Professional, scientific and te… |
|
IntoCell, Inc.
Develops platform technologies for Antibody-Drug Conjugates…
|
287840 | KR | Professional, scientific and te… |
Formosa Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52643/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52643 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52643 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52643 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52643}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Formosa Pharmaceuticals, Inc. (id: 52643)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.